- WebCafé home
- Newly Diagnosed
- Treatment Options
- Non-Invasive blc
- Invasive bladder cancer
- Upper tract TCC
- Metastatic cancer
- Clinical trials
- Survival Guides
- Resources USA & Canada
- Resources Europe
- Clinical trials
- Alternative medicine
- Financial help
- About Us
Intravesical Hyperthermia for non-muscle-invasive bladder cancer - improves effectiveness of Mitomycin C
For a list of institutions in Europe using this method, see below
Ongoing human and animal studies conducted in Europe and Israel dating back some 12 years or more have proven that microwave-induced hyperthermia combined with intravesical mitomycin C is a feasible, effective and safe conservative approach for those with [high risk] multiple and recurrent non-muscle-invasive bladder tumors when other treatment strategies have failed, and/or when cystectomy is contra-indicated or the patient refuses to undergo radical surgery.
Recent clinical experience has shown that treatments with Synergo® are highly efficient and give a lower recurrence rate than traditional methods. Synergo® technology has been approved by the European Standard Authorities (CE) and is now in the process of receiving FDA approval in the US.
In one randomized study, the patients having the new treatment showed a much lower recurrence rate (20%) than patients receiving conventional treatment (70%).
During the last decade this system was mainly used as an alternative to TURB. When clinically used for this indication, this system was shown to be effective, and safe. In a randomized trial it was more effective than intravesical chemotherapy alone.1
With the system now in clinical practice, a 915 MHz microwave applicator is inserted into the bladder via a special catheter. In addition, a set of thermocouples are inserted to control the tempature of the bladder wall layers which are heated to a temperature of 42 +/- 2 degree Celcius (approximately 104 degrees Farenheit +/- 1 degree). The drug is then pumped out and re-instilled, as a way of avoid overheating. Everything is monitored by a computerized unit with special software.
Each treatment lasts one hour, no major systemic side effects are observed, with local side effects being tolerable and temporary; no regional or general anesthetic is required, and patients can resume normal daily activities the same day.
All studies performed to date have shown the benefit of the Synergo® system over TUR or TUR+intravesical chemo with improved clinical results, lower recurrence rates and a reduced need for cystectomy. (see list below)
Synergo® treatments are performed in Germany, Israel and Italy, Holland, Switzerland, Austria, France and Belgium. For more info see article: New Technology For Superficial Bladder Cancer; http://www.medinews.com/GMEDTS32olcgi/ts.cgi?tsurl=0.55.1236.0.0 and manufacturer's website, Medical Enterprises
www.Medical-Enterprises.com Medical Enterprises Europe B.V.
References - Partial List of Published articles-
Thermo-Chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients. Ann Oncol.2005 Apr,16(40:585-9. Moskovitz B, Meyer G, Kravtzov A, Gross M, Kastin A, Biton K, Nativ O.
The Effect of Hyperthermia on Mitomycin-C Induced Cytotoxicity in Four Human Bladder Cancer Cell Lines. Van der Heijden A.G, Cornelius F. J. J, Verhaegh G, O'Donnell M.A, Schalken J.A, Witjes J.A. Eur Urol. 2004 Nov;46(5):670-674.
Preliminary European Results of Local Microwave Hyperthermia and Chemotherapy Treatment in Intermediate or High Risk Superficial Transitional Cell Carcinoma of the Bladder. Van der Heijden A.G, Kiemeney L.A, Gofrit O.N, Nativ O, Sidi A, Leib Z, Colombo R, Naspro R, Pavone M, Baniel J, Hasner F, Witjes J.A. Eur Urol 46:65-72;2004.
Combined Local Bladder Hyperthermia and Intravesical Chemotherapy for the Treatment of High Grade Superficial Bladder Cancer. Gofrit O.N, Shapiro A, Pode D, Sidi A, Nativ O, Leib Z, Witjes J.A, Van Der Heijden A.G, Naspro R, Colombo R.Urol 63(3):466-471;2004.
Multicentric Study Comparing Intravesical Chemotherapy Alone and With Local Microwave Hyperthermia for Prophylaxis of Recurrence of Superficial Transitional Cell Carcinoma. Colombo R, Da Pozzo L.F, Salonia A, Rigatti P, Leib Z, Baniel J, Caldarera E, Pavone-Macaluso M. J Clin Oncol. 21:4270-4276;2003.
* Centers participating in the clinical study.
|Last Updated ( Friday, 14 November 2008 )|